News & Deep Analysis
ADMA

ADMA Biologics Initiates $125M ASR Deal

Published: March 2, 2026
ADMA BIOLOGICS, INC.

Direct News

  • ADMA Biologics (Ticker: ADMA) initiated a $125 million accelerated share repurchase (ASR) on 2026-03-02.
  • The announcement on 2026-03-02 is limited in the provided input to the initiation and aggregate dollar amount of the ASR.

Historical Context

Key prior events in the provided record: - 2026-02-25: CFO retirement and successor appointment. - 2025-11-05: Q3 2025 Financial Results and Business Update, including FDA lot release. The 2026-03-02 ASR initiation is the latest event in this sequence based on the supplied information.

What the announcement states

On 2026-03-02 ADMA Biologics initiated an accelerated share repurchase program with an aggregate commitment of $125 million. The available information supplied for this report contains only the initiation and the dollar size of the ASR; no additional operational, timing, counterparty, or share-quantity details were provided in the input.

Timing and corporate context

This ASR announcement is the company's most recent corporate action as of 2026-03-02. It follows the company's CFO retirement and successor appointment on 2026-02-25, and comes after the company's Q3 2025 Financial Results and Business Update (including FDA lot release) reported on 2025-11-05. The provided inputs do not state any direct link or motive tying the ASR to those earlier events.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at ADMA BIOLOGICS, INC. as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

1

Create Your Free Account

Sign up or log in to access your personal dashboard.

2

Select Your Focus

Use the search bar to find companies like ADMA BIOLOGICS, INC.. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

3

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights